These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 24695088)
1. Estriol-induced fibrinolysis due to the activation of plasminogen to plasmin by nitric oxide synthesis in platelets. Jana P; Maiti S; Kahn NN; Sinha AK Blood Coagul Fibrinolysis; 2015 Apr; 26(3):316-23. PubMed ID: 24695088 [TBL] [Abstract][Full Text] [Related]
2. The role of nitric oxide in aspirin induced thrombolysis in vitro and the purification of aspirin activated nitric oxide synthase from human blood platelets. Karmohapatra SK; Chakraborty K; Kahn NN; Sinha AK Am J Hematol; 2007 Nov; 82(11):986-95. PubMed ID: 17636472 [TBL] [Abstract][Full Text] [Related]
3. Zinc delays clot lysis by attenuating plasminogen activation and plasmin-mediated fibrin degradation. Henderson SJ; Stafford AR; Leslie BA; Kim PY; Vaezzadeh N; Ni R; Fredenburgh JC; Weitz JI Thromb Haemost; 2015 Jun; 113(6):1278-88. PubMed ID: 25789495 [TBL] [Abstract][Full Text] [Related]
4. The role of inhibition of nitric oxide synthesis in the aggregation of platelets due to the stimulated production of thromboxane A2. Banerjee D; Mazumder S; Sinha AK Blood Coagul Fibrinolysis; 2014 Sep; 25(6):585-91. PubMed ID: 25083729 [TBL] [Abstract][Full Text] [Related]
5. The role of leucocytes in the acetyl salicylic acid (aspirin) induced nitric oxide synthesis in the production of interferon-alpha, a potent inhibitor of platelet aggregation and a thrombolytic agent. Bhattacharyya M; Karmohapatra SK; Bhattacharya G; Bhattacharya R; Sinha AK J Thromb Thrombolysis; 2009 Aug; 28(2):173-84. PubMed ID: 18846318 [TBL] [Abstract][Full Text] [Related]
6. Clot lysis time in platelet-rich plasma: method assessment, comparison with assays in platelet-free and platelet-poor plasmas, and response to tranexamic acid. Panes O; Padilla O; Matus V; Sáez CG; Berkovits A; Pereira J; Mezzano D Platelets; 2012; 23(1):36-44. PubMed ID: 21787173 [TBL] [Abstract][Full Text] [Related]
7. Platelet-bound prekallikrein promotes pro-urokinase-induced clot lysis: a mechanism for targeting the factor XII dependent intrinsic pathway of fibrinolysis. Loza JP; Gurewich V; Johnstone M; Pannell R Thromb Haemost; 1994 Mar; 71(3):347-52. PubMed ID: 8029800 [TBL] [Abstract][Full Text] [Related]
8. Pyridoxine improves platelet nitric oxide synthase dysfunction induced by advanced glycation end products in vitro. Han Y; Liu Y; Mi Q; Xie L; Huang Y; Jiang Q; Chen Q; Ferro A; Liu N; Ji Y Int J Vitam Nutr Res; 2010 Jun; 80(3):168-77. PubMed ID: 21234858 [TBL] [Abstract][Full Text] [Related]
9. Pyridoxine increases nitric oxide biosynthesis in human platelets. Wu Y; Liu Y; Han Y; Cui B; Mi Q; Huang Y; Wang L; Jiang Q; Chen Q; Liu N; Ferro A; Ji Y Int J Vitam Nutr Res; 2009 Mar; 79(2):95-103. PubMed ID: 20108211 [TBL] [Abstract][Full Text] [Related]
10. Rapid dissociation of platelet-rich fibrin clots in vitro by a combination of plasminogen activators and antiplatelet agents. Lam SC; Dieter JP; Strebel LC; Taylor TM; Muscolino G; Feinberg H; Le Breton GC J Pharmacol Exp Ther; 1991 Dec; 259(3):1371-8. PubMed ID: 1762085 [TBL] [Abstract][Full Text] [Related]
11. Incorporation of fragment X into fibrin clots renders them more susceptible to lysis by plasmin. Schaefer AV; Leslie BA; Rischke JA; Stafford AR; Fredenburgh JC; Weitz JI Biochemistry; 2006 Apr; 45(13):4257-65. PubMed ID: 16566600 [TBL] [Abstract][Full Text] [Related]
12. Tissue plasminogen activator in human megakaryocytes and platelets: immunocytochemical localization, immunoblotting and zymographic analysis. Jeanneau C; Sultan Y Thromb Haemost; 1988 Jun; 59(3):529-34. PubMed ID: 3142087 [TBL] [Abstract][Full Text] [Related]
14. Role of active center and lysine binding sites of plasmin in plasmin-induced platelet activation and disaggregation. Lu H; Soria C; Li H; Soria J; Lijnen HR; Perrot JY; Caen JP Thromb Haemost; 1991 Jan; 65(1):67-72. PubMed ID: 1827215 [TBL] [Abstract][Full Text] [Related]
15. RGDFAP: platelet aggregation inhibitory and profibrinolytic hybrid peptide (RGDF coupled with the carboxy terminal part of alpha 2-antiplasmin) enhances plasminogen binding to platelets. Udvardy M; Schwartzott D; Jackson K; Posan E; Rak K; McKee PA Blood Coagul Fibrinolysis; 1995 Jul; 6(5):481-5. PubMed ID: 8589217 [TBL] [Abstract][Full Text] [Related]
16. [Inhibition of esterase by L-lysine, the activator and fibrinolytic activity of the plasmin-streptokinase activator complex]. Aĭsina RB; Gaĭsarian ES; Snitko IaE; Varfolomeev SD Bioorg Khim; 1994 Feb; 20(2):182-9. PubMed ID: 8155080 [TBL] [Abstract][Full Text] [Related]
17. Increased nitric oxide production in platelets from severe chronic renal failure patients. Siqueira MA; Brunini TM; Pereira NR; Martins MA; Moss MB; Santos SF; Lugon JR; Mendes-Ribeiro AC Can J Physiol Pharmacol; 2011 Feb; 89(2):97-102. PubMed ID: 21326340 [TBL] [Abstract][Full Text] [Related]
18. Interactions of staphylokinase with human platelets. Lijnen HR; Van Hoef B; Collen D Thromb Haemost; 1995 Mar; 73(3):472-7. PubMed ID: 7667831 [TBL] [Abstract][Full Text] [Related]
19. Fluorogenic fibrinogen and fibrin facilitate macromolecular assembly and dynamic assay of picomolar levels of plasminogen activators under well mixed conditions. Wu JH; Diamond SL Thromb Haemost; 1995 Aug; 74(2):711-7. PubMed ID: 8585011 [TBL] [Abstract][Full Text] [Related]
20. Plasminogen associates with phosphatidylserine-exposing platelets and contributes to thrombus lysis under flow. Whyte CS; Swieringa F; Mastenbroek TG; Lionikiene AS; Lancé MD; van der Meijden PE; Heemskerk JW; Mutch NJ Blood; 2015 Apr; 125(16):2568-78. PubMed ID: 25712989 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]